Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12–15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollyea, Daniel A., Tallman, Martin S., de Botton, Stéphane, Kantarjian, Hagop M., Collins, Robert, Stein, Anthony S., Frattini, Mark G., Xu, Qiang, Tosolini, Alessandra, See, Wendy L., MacBeth, Kyle J., Agresta, Samuel V., Attar, Eyal C., DiNardo, Courtney D., Stein, Eytan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724489/
https://www.ncbi.nlm.nih.gov/pubmed/30967620
http://dx.doi.org/10.1038/s41375-019-0472-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724489/
https://www.ncbi.nlm.nih.gov/pubmed/30967620
http://dx.doi.org/10.1038/s41375-019-0472-2

Ejemplares similares